

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

[ ] Check this box if no longer  
subject to Section 16. Form 4 or  
Form 5 obligations may  
continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <b>BURR ROBERT L</b>  (Last) (First) (Middle) <b>C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, THIRD FLOOR</b>  (Street) <b>BRIDGEWATER, NJ 08807</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>Amneal Pharmaceuticals, Inc. [ AMRX ]</b>  3. Date of Earliest Transaction (MM/DD/YYYY) <b>5/4/2018</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director _____ 10% Owner <input type="checkbox"/> Officer (give title below) _____ Other (specify below)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
4. If Amendment, Date Original Filed (MM/DD/YYYY)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	5/4/2018		A		60475	A	(1)	60475	D	
Class A Common Stock	5/4/2018		A		6057	A	(2)	6057	I	By the Robert L. Burr IRA Account

**Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V			Date Exercisable	Expiration Date				
Stock Option	\$16.40	5/4/2018		A		10575	(3)	5/16/2027	Class A Common Stock	10575	(4)	10575	D
Stock Option	\$30.33	5/4/2018		A		10575	(3)	5/17/2026	Class A Common Stock	10575	(4)	10575	D
Stock Option	\$44.85	5/4/2018		A		7300	(3)	5/12/2025	Class A Common Stock	7300	(4)	7300	D
Stock Option	\$25.24	5/4/2018		A		11500	(3)	5/14/2024	Class A Common Stock	11500	(4)	11500	D
Stock Option	\$17.99	5/4/2018		A		12000	(3)	5/15/2023	Class A Common Stock	12000	(4)	12000	D
Stock Option	\$20.90	5/4/2018		A		10000	(3)	5/23/2022	Class A Common Stock	10000	(4)	10000	D
Stock Option	\$27.97	5/4/2018		A		10000	(3)	5/11/2021	Class A Common Stock	10000	(4)	10000	D
Stock Option	\$20.30	5/4/2018		A		10000	(3)	5/26/2020	Class A Common Stock	10000	(4)	10000	D
Stock Option	\$6.55	5/4/2018		A		30000	(3)	5/20/2019	Class A Common Stock	30000	(4)	30000	D
Stock Option	\$15.01	5/7/2018		A		24977	(5)	5/7/2028	Class A Common Stock	24977	\$0.00	24977	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)															
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date	Title				
Restricted Stock Units	(6)	5/7/2018		A		6107		(7)	(7)	Class A Common Stock	6107	\$0.00	6107	D	

#### Explanation of Responses:

- (1) Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
- (2) Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA.
- (3) The option is vested and currently exercisable.
- (4) Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
- (5) The option vests in four equal annual installments beginning on May 07, 2019.
- (6) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- (7) The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

#### Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BURR ROBERT L C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD, THIRD FLOOR BRIDGEWATER, NJ 08807	X			

#### Signatures

/s/ Bryan M. Reasons, Attorney-in-Fact

5/8/2018

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.